In:
Cancer, Wiley, Vol. 123, No. 6 ( 2017-03-15), p. 1011-1017
Abstract:
The results of the current study demonstrate that the combination of capecitabine and oxaliplatin with bevacizumab is a safe and effective regimen for the treatment of patients with advanced small bowel adenocarcinoma and ampullary adenocarcinoma, with an overall response rate of 48.3%, a median progression‐free survival of 8.7 months, and a median overall survival of 12.9 months. To the authors' knowledge, this is the first prospective clinical trial evaluating the use of targeted therapies in patients with small bowel adenocarcinoma and ampullary adenocarcinoma.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1